Nova Leap Health Corp. (TSXV:NLH)
0.4350
-0.0050 (-1.14%)
Jul 31, 2026, 12:58 PM EST
Nova Leap Health Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 38 | 24 | 24 | 26 | 22 | 48 | |
Market Cap Growth | 93.33% | 3.70% | -8.75% | 19.87% | -55.44% | -1.71% |
Enterprise Value | 39.68 | 26.42 | 25.19 | 26.38 | 25.09 | 53.9 |
Last Close Price | 0.44 | 0.28 | 0.27 | 0.30 | 0.25 | 0.61 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 127.77 | - | 11.76 | - | - | 24.13 |
Forward PE | - | 18.95 | 18.95 | 6.05 | 6.16 | 16.07 |
PS Ratio | 0.84 | 0.57 | 0.64 | 0.74 | 0.56 | 1.80 |
PB Ratio | 1.43 | 0.94 | 0.90 | 1.07 | 0.85 | 2.07 |
P/TBV Ratio | 23.95 | 17.04 | 14.27 | 8.52 | 13.13 | - |
P/FCF Ratio | 15.42 | 11.44 | 12.05 | 9.17 | 16.73 | 17.56 |
P/OCF Ratio | 15.42 | 11.44 | 11.84 | 9.05 | 15.56 | 17.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.88 | 0.61 | 0.68 | 0.76 | 0.66 | 2.00 |
EV/EBITDA Ratio | - | - | - | 46.86 | 7.65 | 20.38 |
EV/EBIT Ratio | - | - | - | - | 17.41 | 34.63 |
EV/FCF Ratio | 16.11 | 12.37 | 12.88 | 9.36 | 19.47 | 19.56 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.14 | 0.12 | 0.06 | 0.19 | 0.31 |
Debt / EBITDA Ratio | - | - | - | 3.08 | 1.60 | 2.92 |
Debt / FCF Ratio | 1.61 | 1.88 | 1.85 | 0.62 | 4.09 | 2.80 |
Net Debt / Equity Ratio | 0.06 | 0.08 | 0.06 | 0.02 | 0.14 | 0.24 |
Net Debt / EBITDA Ratio | -2.27 | -5.27 | -4.01 | 0.97 | 1.08 | 2.09 |
Net Debt / FCF Ratio | 0.69 | 0.92 | 0.82 | 0.19 | 2.74 | 2.01 |
Asset Turnover | 1.37 | 1.37 | 1.19 | 1.17 | 1.11 | 0.96 |
Quick Ratio | 0.94 | 0.89 | 0.96 | 1.43 | 0.92 | 0.91 |
Current Ratio | 1.02 | 0.96 | 1.06 | 1.59 | 1.00 | 0.96 |
Return on Equity (ROE) | 1.12% | -1.02% | 7.56% | -5.72% | -4.50% | 12.43% |
Return on Assets (ROA) | -1.59% | -14.41% | -3.49% | -1.92% | 2.41% | 6.29% |
Return on Invested Capital (ROIC) | -1.83% | -16.59% | -3.98% | -2.15% | 2.77% | 7.79% |
Return on Capital Employed (ROCE) | -6.69% | -5.69% | -4.51% | -2.36% | 5.24% | 7.26% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.78% | - | 8.50% | - | - | 4.14% |
FCF Yield | 6.49% | 8.74% | 8.30% | 10.91% | 5.98% | 5.70% |
Buyback Yield / Dilution | -0.80% | -0.60% | -0.68% | -5.83% | -4.90% | -16.89% |
Total Shareholder Return | -0.80% | -0.60% | -0.68% | -5.83% | -4.90% | -16.89% |